Evidence map›Paper›PMID 34491404›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2022

Influence of sarcopenia, clinical data, and 2-[

Reut Anconina, Claudia Ortega, Ur Metser, Zhihui Amy Liu, Chihiro Suzuki, Micheal McInnis, Gail E Darling, Rebecca Wong, Kirsty Taylor, Jonathan Yeung and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. IntegratingBMC cancer · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Nanomedicine in Lung Cancer Immunotherapy.Frontiers in bioengineering and biotechnology · 2023
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Reut AnconinaDepartment of Medical Imaging, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave, Toronto, ON, M4N 3M5, Canada. anconinar@gmail.com.
Claudia OrtegaJoint Department of Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada.
Ur MetserJoint Department of Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada.
Zhihui Amy LiuDepartment of Biostatistics, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.
Chihiro SuzukiDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.
Micheal McInnisJoint Department of Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada.
Gail E DarlingDivision of Thoracic Surgery, Department of Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada.
Rebecca WongDepartment of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.
Kirsty TaylorDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.
Jonathan YeungDivision of Thoracic Surgery, Department of Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada.
Eric X ChenDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.
Carol J SwallowDepartment of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and Sinai Health System, University of Toronto, Toronto, Canada.
Jaspreet BajwaUniversity of Toronto, Toronto, Canada.
Raymond W JangDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.
Elena ElimovaDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.
Patrick Veit-HaibachJoint Department of Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada.
University Health Network · CAUniversity of Toronto · CAPrincess Margaret Cancer Centre · CAToronto General Hospital · CAHealth Sciences Centre · CASinai Health System · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo determine the prognostic value of sarcopenia measurements done on staging 2-[18F] FDG PET/CT together with metabolic activity of the tumor in patients with adenocarcinoma esophagogastric cancer with surgical treatment.

methodsPatients with early-stage, surgically treated esophageal adenocarcinoma and available pre-treatment 2-[18F] FDG PET/CT were included. The standard uptake value (SUV) and SUV normalized by lean body mass (SUL) were recorded. Skeletal muscle index (SMI) was measured at the L3 level on the CT component of the PET/CT. Sarcopenia was defined as SMI < 34.4cm

resultsOf the included 145 patients. 30% were sarcopenic at baseline. On the univariable Cox proportional hazards analysis, ECOG, surgical T and N staging, lymphovascular invasion (LVI) positive lymph nodes, and sarcopenia were significant prognostic factors concerning RFS and OS. On multivariable Cox regression analysis, surgical N staging (p = 0.025) and sarcopenia (p = 0.022) remained significant poor prognostic factors for OS and RFS. Combining the clinical parameters with the imaging-derived nutritional evaluation of the patient but not metabolic parameters of the tumor showed improved predictive ability for OS and RFS.

conclusionCombining the patients' imaging-derived sarcopenic status with standard clinical data, but not metabolic parameters, offered an overall improved prognostic value concerning OS and RFS.

Indexed as

AdenocarcinomaEsophageal NeoplasmsSarcopeniaStomach NeoplasmsFemaleFluorodeoxyglucose F18HumansMalePositron Emission Tomography Computed TomographyPrognosisRetrospective StudiesTomography, X-Ray ComputedFluorodeoxyglucose F18Esophageal adenocarcinomaOutcome predictionPET/CTSarcopenia

Identifiers

PMID34491404
OpenAlexW3198371217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.